Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Genetic alterations in TRAF3 and CYLD that regulate nuclear factor κB and interferon signaling define head and neck cancer subsets harboring human papillomavirus.

Chen T, Zhang J, Chen Z, Van Waes C.

Cancer. 2017 May 15;123(10):1695-1698. doi: 10.1002/cncr.30659. Epub 2017 Mar 13. No abstract available.

PMID:
28295216
2.

Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCL patients.

Wang J, Zhou M, Zhang QG, Xu J, Lin T, Zhou RF, Li J, Yang YG, Chen B, Ouyang J.

Oncotarget. 2017 Feb 7;8(6):9708-9716. doi: 10.18632/oncotarget.14182.

3.

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.

Offner F, Samoilova O, Osmanov E, Eom HS, Topp MS, Raposo J, Pavlov V, Ricci D, Chaturvedi S, Zhu E, van de Velde H, Enny C, Rizo A, Ferhanoglu B.

Blood. 2015 Oct 15;126(16):1893-901. doi: 10.1182/blood-2015-03-632430. Epub 2015 Jul 31.

4.

NF-κB and stat3 transcription factor signatures differentiate HPV-positive and HPV-negative head and neck squamous cell carcinoma.

Gaykalova DA, Manola JB, Ozawa H, Zizkova V, Morton K, Bishop JA, Sharma R, Zhang C, Michailidi C, Considine M, Tan M, Fertig EJ, Hennessey PT, Ahn J, Koch WM, Westra WH, Khan Z, Chung CH, Ochs MF, Califano JA.

Int J Cancer. 2015 Oct 15;137(8):1879-89. doi: 10.1002/ijc.29558. Epub 2015 Jun 23.

5.

CCR 20th anniversary commentary: Preclinical study of proteasome inhibitor bortezomib in head and neck cancer.

Allen CT, Conley B, Sunwoo JB, Van Waes C.

Clin Cancer Res. 2015 Mar 1;21(5):942-3. doi: 10.1158/1078-0432.CCR-14-2550.

6.
7.

The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.

Johnson DE.

Endocr Relat Cancer. 2015 Feb;22(1):T1-17. doi: 10.1530/ERC-14-0005. Epub 2014 Mar 21. Review.

8.

HSP90 Inhibitor SNX5422/2112 Targets the Dysregulated Signal and Transcription Factor Network and Malignant Phenotype of Head and Neck Squamous Cell Carcinoma.

Friedman JA, Wise SC, Hu M, Gouveia C, Vander Broek R, Freudlsperger C, Kannabiran VR, Arun P, Mitchell JB, Chen Z, Van Waes C.

Transl Oncol. 2013 Aug 1;6(4):429-41. Print 2013 Aug.

9.

Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma.

Dunleavy K, Grant C, Wilson WH.

Ther Adv Hematol. 2013 Feb;4(1):43-57. doi: 10.1177/2040620712464508.

10.

Aberrant IKKα and IKKβ cooperatively activate NF-κB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer.

Nottingham LK, Yan CH, Yang X, Si H, Coupar J, Bian Y, Cheng TF, Allen C, Arun P, Gius D, Dang L, Van Waes C, Chen Z.

Oncogene. 2014 Feb 27;33(9):1135-47. doi: 10.1038/onc.2013.49. Epub 2013 Mar 4.

11.

Treatment of diffuse large B cell lymphoma.

Kwak JY.

Korean J Intern Med. 2012 Dec;27(4):369-77. doi: 10.3904/kjim.2012.27.4.369. Epub 2012 Nov 27. Review.

12.

Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN.

Leinung M, Hirth D, Tahtali A, Diensthuber M, Stöver T, Wagenblast J.

Oncol Lett. 2012 Dec;4(6):1305-1308. Epub 2012 Sep 20.

13.

Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.

Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE.

Clin Cancer Res. 2012 Oct 15;18(20):5639-49. doi: 10.1158/1078-0432.CCR-12-1213. Epub 2012 Aug 28.

14.

Targeting NF-κB in mouse models of lung adenocarcinoma.

Van Waes C.

Cancer Discov. 2011 Aug;1(3):200-2. doi: 10.1158/2159-8290.CD-11-0159.

15.
16.

TNF-α promotes c-REL/ΔNp63α interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancer.

Lu H, Yang X, Duggal P, Allen CT, Yan B, Cohen J, Nottingham L, Romano RA, Sinha S, King KE, Weinberg WC, Chen Z, Van Waes C.

Cancer Res. 2011 Nov 1;71(21):6867-77. doi: 10.1158/0008-5472.CAN-11-2460. Epub 2011 Sep 20.

17.

Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.

Argiris A, Duffy AG, Kummar S, Simone NL, Arai Y, Kim SW, Rudy SF, Kannabiran VR, Yang X, Jang M, Chen Z, Suksta N, Cooley-Zgela T, Ramanand SG, Ahsan A, Nyati MK, Wright JJ, Van Waes C.

Clin Cancer Res. 2011 Sep 1;17(17):5755-64. doi: 10.1158/1078-0432.CCR-11-0861. Epub 2011 Jul 12.

18.
19.

ΔNp63 versatilely regulates a Broad NF-κB gene program and promotes squamous epithelial proliferation, migration, and inflammation.

Yang X, Lu H, Yan B, Romano RA, Bian Y, Friedman J, Duggal P, Allen C, Chuang R, Ehsanian R, Si H, Sinha S, Van Waes C, Chen Z.

Cancer Res. 2011 May 15;71(10):3688-700. doi: 10.1158/0008-5472.CAN-10-3445. Erratum in: Cancer Res. 2011 Dec 1;71(23):7323.

20.

Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma.

Wilken R, Veena MS, Wang MB, Srivatsan ES.

Mol Cancer. 2011 Feb 7;10:12. doi: 10.1186/1476-4598-10-12. Review.

Supplemental Content

Support Center